MCID: SCN036
MIFTS: 51

Secondary Progressive Multiple Sclerosis

Categories: Neuronal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 55 15
Multiple Sclerosis, Secondary Progressive 73
Multiple Sclerosis, Chronic Progressive 44
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 44 D020528
SNOMED-CT 68 425500002
UMLS 73 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to meningitis and relapsing-remitting multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dimethyl fumarate and Interferon beta-1b have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and cortex, and related phenotypes are cellular and hematopoietic system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 meningitis 28.9 CCL2 CD40LG IL10 MMP9
2 relapsing-remitting multiple sclerosis 28.1 HNRNPA1 IFNB1 IL10 IL4 MBP MMP9
3 multiple sclerosis 27.2 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IL10
4 scapuloperoneal myopathy, x-linked dominant 11.2
5 auditory system cancer 10.9 ENO2 MMP9
6 lentigo maligna melanoma 10.8 MMP9 S100B
7 intracranial cysts 10.8 ENO2 S100B
8 acute transverse myelitis 10.8 IL10 MMP9
9 bednar tumor 10.8 ENO2 S100B
10 finger agnosia 10.8 ENO2 MBP
11 epithelioid malignant peripheral nerve sheath tumor 10.8 ENO2 S100B
12 ross river fever 10.8 CD40LG IL10
13 neonatal hypoxic and ischemic brain injury 10.8 ENO2 MBP
14 ossifying fibromyxoid tumor 10.7 ENO2 S100B
15 retroperitoneal neuroblastoma 10.7 ENO2 IFNB1
16 meningovascular neurosyphilis 10.7 CD40LG MBP
17 folliculotropic mycosis fungoides 10.7 CCR3 CXCR3
18 post-vaccinal encephalitis 10.7 CD40LG MBP
19 tropical spastic paraparesis 10.7 CXCR3 IL10 MMP9
20 head injury 10.7 ENO2 S100B
21 bronchiolitis obliterans 10.7 CXCR3 IL10 MMP9
22 zika fever 10.7 CD40LG IFNB1
23 sporotrichosis 10.6 CD40LG IL10
24 appendicitis 10.6 ENO2 IL10 MMP9
25 transverse myelitis 10.6 IL10 MBP MMP9
26 balo concentric sclerosis 10.6 IFNB1 MBP
27 necrotizing ulcerative gingivitis 10.6 CD40LG IL10
28 opsoclonus-myoclonus syndrome 10.6 CXCL10 CXCR3
29 bacterial meningitis 10.6 IL10 MMP9 S100B
30 allergic encephalomyelitis 10.6 CXCL10 MBP
31 neurosyphilis 10.6 CXCL10 IL10
32 cow milk allergy 10.6 CCR5 IL10
33 melanotic neuroectodermal tumor 10.6 ENO2 S100B
34 dysgammaglobulinemia 10.5 CD40LG MBP
35 optic nerve glioma 10.5 ENO2 MBP S100B
36 cerebral primitive neuroectodermal tumor 10.5 ENO2 IFNB1 S100B
37 mucocutaneous leishmaniasis 10.5 CCR5 IL10
38 middle cerebral artery infarction 10.5 CD40LG ENO2 S100B
39 tropical endomyocardial fibrosis 10.5 IL10 IL4
40 pineocytoma 10.5 ENO2 S100B
41 hyperlucent lung 10.4 IL10 IL4
42 tungiasis 10.4 IL10 IL4
43 endomyocardial fibrosis 10.4 IL10 IL4
44 japanese spotted fever 10.4 CD40LG CXCL10
45 tick-borne encephalitis 10.4 CCR5 CXCL10 IL10
46 lymphoproliferative syndrome 2 10.3 CD40LG CXCL10 CXCR3
47 retinitis pigmentosa 22 10.3 IL10 IL4
48 baylisascariasis 10.3 IL10 IL4
49 acute disseminated encephalomyelitis 10.3 IL10 MBP
50 traumatic brain injury 10.3 ENO2 IL10 MBP S100B

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 IL4 CXCL10 CXCR3 CCR2 ENO2 CCR3
2 hematopoietic system MP:0005397 10.11 IL4 CXCL10 CXCR3 CCR2 CCR3 IFNB1
3 homeostasis/metabolism MP:0005376 10.1 IL4 CXCL10 CXCR3 CCR2 CCR3 IFNB1
4 immune system MP:0005387 10.03 CXCL10 CCL2 CXCR3 CCR2 CCR3 IFNB1
5 nervous system MP:0003631 9.65 CD40LG IL4 CXCL10 CCR2 ENO2 IFNB1
6 neoplasm MP:0002006 9.63 CXCR3 CCR2 IFNB1 CCR5 IL10 MMP9
7 respiratory system MP:0005388 9.17 IL4 CXCR3 CCR2 ENO2 CCR3 IL10

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
2
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
3
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Dermatologic Agents Phase 4,Phase 3,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
7 Potassium Channel Blockers Phase 4,Phase 3
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
9 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
10 glucocorticoids Phase 4,Phase 3,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 3,Phase 1 50-24-8 5755
17
Simvastatin Approved Phase 3,Phase 2 79902-63-9 54454
18
Natalizumab Approved, Investigational Phase 3,Phase 2,Phase 1 189261-10-7
19
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
21 Alkylating Agents Phase 3
22 Antiemetics Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Alkylating Phase 3
24 Antirheumatic Agents Phase 3,Phase 1,Phase 2
25 Autonomic Agents Phase 3,Phase 2,Phase 1
26 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
27 Methylprednisolone acetate Phase 3,Phase 1
28 Methylprednisolone Hemisuccinate Phase 3,Phase 1
29 Neuroprotective Agents Phase 3,Phase 2,Phase 1
30 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
31 Prednisolone acetate Phase 3,Phase 1
32 Prednisolone hemisuccinate Phase 3,Phase 1
33 Prednisolone phosphate Phase 3,Phase 1
34 Protective Agents Phase 3,Phase 2,Phase 1
35 Antioxidants Phase 2, Phase 3,Phase 1
36 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
37 Thioctic Acid Phase 2, Phase 3,Phase 1
38 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
39 Vitamin B Complex Phase 2, Phase 3,Phase 1
40 Vitamins Phase 2, Phase 3,Phase 1,Not Applicable
41 Anticholesteremic Agents Phase 3,Phase 2
42 Antimetabolites Phase 3,Phase 2,Phase 1
43 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3,Phase 2
44 Hypolipidemic Agents Phase 3,Phase 2,Phase 1
45 Lipid Regulating Agents Phase 3,Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 3,Phase 2,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1
48 Antiviral Agents Phase 3,Phase 2,Phase 1
49 Interferon-beta Phase 3,Phase 2
50 interferons Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
2 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
3 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
4 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4 Fampridine;Placebo
5 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
6 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
7 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
8 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
9 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
10 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
11 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
12 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
13 Multiple Sclerosis-Simvastatin Trial 2 Not yet recruiting NCT03387670 Phase 3 Simvastatin;Placebo
14 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
15 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
16 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
17 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
18 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
19 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
20 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
21 Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
22 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
23 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
24 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
25 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
26 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
27 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
28 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
29 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo oral capsule
30 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
31 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
32 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
33 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
34 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis Completed NCT01517282 Phase 1, Phase 2
35 Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Recruiting NCT02308137 Phase 2 Domperidone
36 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
37 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
38 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
39 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
40 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Active, not recruiting NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
41 A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients Not yet recruiting NCT03560739 Phase 2 OMB157
42 Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Terminated NCT01212094 Phase 1, Phase 2 Rituximab
43 Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT01181089 Phase 1, Phase 2
44 Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01381354 Phase 1
45 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Completed NCT00559702 Phase 1 natalizumab
46 A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Completed NCT02253264 Phase 1 Rituximab
47 Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Completed NCT00813969 Phase 1
48 Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis Completed NCT00997438 Phase 1
49 Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis Recruiting NCT01647321 Phase 1
50 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis Recruiting NCT03283826 Phase 1

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

41
Brain, B Cells, Cortex, T Cells, Thyroid, Myeloid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 117)
# Title Authors Year
1
Natalizumab in secondary progressive multiple sclerosis. ( 29545068 )
2018
2
Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. ( 29957351 )
2018
3
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. ( 29576505 )
2018
4
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
5
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. ( 29545067 )
2018
6
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. ( 29968175 )
2018
7
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. ( 29768414 )
2018
8
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. ( 29846780 )
2018
9
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study. ( 29177070 )
2017
10
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort. ( 29111873 )
2017
11
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. ( 28429241 )
2017
12
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis. ( 29128442 )
2017
13
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. ( 28801580 )
2017
14
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. ( 28594298 )
2017
15
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
16
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. ( 28600189 )
2017
17
Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis. ( 28521618 )
2017
18
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. ( 29138536 )
2017
19
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. ( 28905255 )
2017
20
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
21
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. ( 28145395 )
2017
22
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. ( 28572730 )
2017
23
Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. ( 28838904 )
2017
24
Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. ( 28601572 )
2017
25
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
26
Expression of DNA methylation genes in secondary progressive multiple sclerosis. ( 26711572 )
2016
27
Secondary Progressive Multiple Sclerosis: Definition and Measurement. ( 27166830 )
2016
28
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. ( 27996064 )
2016
29
Defining secondary progressive multiple sclerosis. ( 27401521 )
2016
30
Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. ( 27229156 )
2016
31
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. ( 26788129 )
2016
32
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. ( 27636543 )
2016
33
The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. ( 27507559 )
2016
34
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis. ( 27408797 )
2016
35
HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. ( 27917400 )
2016
36
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. ( 26943957 )
2016
37
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. ( 27803641 )
2016
38
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2016
39
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2016
40
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. ( 27739247 )
2016
41
Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. ( 27570566 )
2016
42
RORI^t Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. ( 27413074 )
2016
43
Correction to: The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 27032440 )
2016
44
Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients. ( 27919195 )
2016
45
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. ( 27965675 )
2016
46
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. ( 27685028 )
2016
47
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. ( 26733423 )
2016
48
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. ( 27430119 )
2016
49
The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 26692498 )
2016
50
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. ( 26943959 )
2016

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6
(show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh37 Chromosome 12, 54677631: 54677631
2 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh38 Chromosome 12, 54283847: 54283847
3 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh37 Chromosome 12, 54677637: 54677637
4 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh38 Chromosome 12, 54283853: 54283853
5 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
6 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
7 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
8 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
9 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh37 Chromosome 12, 54677667: 54677667
10 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh38 Chromosome 12, 54283883: 54283883
11 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh37 Chromosome 12, 54677675: 54677675
12 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh38 Chromosome 12, 54283891: 54283891
13 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685
14 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh38 Chromosome 12, 54283901: 54283901
15 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh37 Chromosome 12, 54677694: 54677694
16 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh38 Chromosome 12, 54283910: 54283910
17 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh37 Chromosome 12, 54677697: 54677697
18 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh38 Chromosome 12, 54283913: 54283913
19 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh37 Chromosome 12, 54677728: 54677728
20 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh38 Chromosome 12, 54283944: 54283944
21 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh37 Chromosome 12, 54677730: 54677730
22 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh38 Chromosome 12, 54283946: 54283946
23 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh37 Chromosome 12, 54677740: 54677740
24 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh38 Chromosome 12, 54283956: 54283956
25 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Likely pathogenic rs483353037 GRCh37 Chromosome 12, 54677742: 54677742
26 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Likely pathogenic rs483353037 GRCh38 Chromosome 12, 54283958: 54283958
27 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh37 Chromosome 12, 54677745: 54677745
28 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh38 Chromosome 12, 54283961: 54283961
29 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh37 Chromosome 12, 54677746: 54677746
30 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh38 Chromosome 12, 54283962: 54283962

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCL2 CCR2 CCR5 CD40LG CXCL10 IFNB1
2
Show member pathways
13.72 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
3
Show member pathways
13.52 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
4
Show member pathways
13.27 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
5
Show member pathways
13.23 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
6
Show member pathways
13.17 CCL2 CCR2 CCR5 CD40LG CXCL10 IFNB1
7
Show member pathways
13.09 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
8
Show member pathways
12.75 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
9
Show member pathways
12.45 CCR3 CCR5 IFNB1 MMP9
10 12.45 CCL2 CCR2 CD40LG CXCL10 IL10 IL4
11
Show member pathways
12.32 CCR5 CD40LG IL10 IL4
12
Show member pathways
12.21 CCL2 CXCL10 IL4 MMP9
13
Show member pathways
12.14 CCR5 CD40LG IL10 IL4
14 11.87 CCR3 IL10 IL4
15 11.87 CCL2 IL10 IL4 MMP9
16 11.83 CCL2 CXCL10 MMP9
17 11.79 CCR2 CCR5 IFNB1 IL10
18 11.71 CCL2 CCR2 CXCL10 IL4 MBP MMP9
19 11.7 CXCR3 IL10 IL4
20 11.56 CD40LG IL10 IL4
21
Show member pathways
11.5 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
22 11.45 CCL2 CCR2 CCR3 IL4 MMP9
23 11.42 CCL2 CD40LG IL10
24 11.19 IFNB1 IL10 IL4
25 11.13 CCL2 CCR2 CD40LG MMP9
26 11.07 CCL2 CCR3 MMP9
27 10.79 CCL2 CCR2 CCR5 CXCL10 IL10 IL4

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 CCL2 CD40LG CXCL10 IFNB1 IL10 IL4
2 neuronal cell body GO:0043025 9.56 CCR2 ENO2 MBP S100B
3 external side of plasma membrane GO:0009897 9.35 CCR2 CCR5 CD40LG CXCL10 CXCR3
4 extracellular space GO:0005615 9.28 CCL2 CD40LG CXCL10 ENO2 IFNB1 IL10

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 CCL2 CD40LG CXCL10 IFNB1 IL10 IL4
2 immune response GO:0006955 9.86 CCL2 CCR2 CCR5 CD40LG CXCL10 IL10
3 cell surface receptor signaling pathway GO:0007166 9.83 CCL2 CCR5 CXCL10 CXCR3 IFNB1
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.8 CCR2 CCR3 CCR5 CXCR3
5 chemotaxis GO:0006935 9.8 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
6 defense response GO:0006952 9.79 CCR5 CXCL10 IFNB1
7 cellular response to lipopolysaccharide GO:0071222 9.78 CCL2 CCR5 CXCL10 IL10
8 inflammatory response GO:0006954 9.76 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
9 humoral immune response GO:0006959 9.71 CCL2 CCR2 IFNB1
10 cellular defense response GO:0006968 9.7 CCR2 CCR3 CCR5
11 B cell differentiation GO:0030183 9.67 CD40LG IFNB1 IL10 IL4
12 B cell proliferation GO:0042100 9.63 CD40LG IFNB1 IL10
13 positive regulation of endothelial cell apoptotic process GO:2000353 9.61 CCL2 CD40LG
14 positive regulation of monocyte chemotaxis GO:0090026 9.61 CCR2 CXCL10
15 dendritic cell chemotaxis GO:0002407 9.6 CCR2 CCR5
16 cellular homeostasis GO:0019725 9.58 CCL2 CCR2
17 T cell chemotaxis GO:0010818 9.58 CXCL10 CXCR3
18 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.57 IL10 MBP
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL10 IL4
20 cytokine-mediated signaling pathway GO:0019221 9.56 CCL2 CCR2 CCR5 CXCL10 IFNB1 IL10
21 type 2 immune response GO:0042092 9.55 IL10 IL4
22 regulation of isotype switching GO:0045191 9.51 IL10 IL4
23 chemokine-mediated signaling pathway GO:0070098 9.1 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
24 G-protein coupled receptor signaling pathway GO:0007186 10.07 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.67 CCR2 CCR3 CCR5 CXCR3
2 cytokine activity GO:0005125 9.43 CCL2 CD40LG CXCL10 IFNB1 IL10 IL4
3 C-C chemokine receptor activity GO:0016493 9.33 CCR2 CCR3 CCR5
4 C-C chemokine binding GO:0019957 9.32 CCR3 CCR5
5 CCR2 chemokine receptor binding GO:0031727 9.26 CCL2 CCR2
6 chemokine receptor activity GO:0004950 8.92 CCR2 CCR3 CCR5 CXCR3

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....